Head-to-head comparison
| Property | Retatrutide | Survodutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Research Only |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~6 days | ~1 week (supports once-weekly dosing; Tmax ~51h in dogs, extended mean residence time) |
| Mol. Weight | 4,894.58 Da | — |
| Side Effects | Nausea (most common, dose-dependent), Vomiting, Diarrhea | Nausea, Vomiting, Diarrhea |
Key differences
- Receptor targets: Retatrutide activates GLP-1, GIP, and glucagon receptors (triple agonist); survodutide activates GLP-1 and glucagon receptors (dual agonist). Retatrutide's added GIP agonism potentiates insulin release and may reduce GLP-1-associated nausea.
- Efficacy: Retatrutide Phase 3 TRIUMPH-4 showed 26.4-28.7% weight loss at 40 weeks; survodutide Phase 2 showed 14.9% at 4.8 mg over 46 weeks. The gap is substantial, though trials differ in design and duration.
- MASH/NASH potential: Both target liver disease through glucagon-mediated hepatic fat clearance. Survodutide has FDA Fast Track Designation for MASH and Phase 2 data showing 62% histological improvement at 4.8 mg versus 14% placebo. Retatrutide Phase 3 MASH results are pending.
- Developer: Retatrutide is developed by Eli Lilly; survodutide by Boehringer Ingelheim and Zealand Pharma.
- Dosing: Both are once-weekly subcutaneous injections. Retatrutide titrates from 2 mg to 8-12 mg; survodutide titrates from 0.6 mg to 4.8 mg.
- Half-life: Retatrutide has a half-life of approximately 6 days; survodutide approximately 1 week. Both support once-weekly dosing.
- Side effects: Both share GLP-1-class GI side effects. Retatrutide's additional GIP component may mitigate some nausea, while survodutide's side effect profile is consistent with GLP-1/glucagon dual agonism.
The verdict
Retatrutide has demonstrated markedly greater weight loss in clinical trials, consistent with its triple-receptor mechanism providing additional metabolic pathways beyond what dual GLP-1/glucagon agonism offers. Survodutide's advantage is its FDA Fast Track Designation for MASH and early but compelling liver histology data. Both compounds are investigational, and the clinical development timelines and ultimate regulatory outcomes remain uncertain. For pure weight loss, retatrutide's Phase 3 data is more impressive; for liver-specific disease, survodutide has the more targeted regulatory path.
Frequently asked questions
Both include glucagon receptor activation for hepatic fat clearance, but retatrutide is a triple agonist (GLP-1 + GIP + glucagon) while survodutide is a dual agonist (GLP-1 + glucagon). Retatrutide's additional GIP agonism enhances insulin sensitization and may reduce GLP-1-related nausea, contributing to its higher observed weight loss.
Retatrutide has shown substantially more weight loss in trials: 26.4-28.7% in Phase 3 TRIUMPH-4 at 40 weeks versus survodutide's 14.9% in Phase 2 at 46 weeks. The difference is large, though trial designs, populations, and doses are not directly comparable.
Neither is FDA-approved as of April 2026. Both are investigational compounds in Phase 3 clinical trials. Survodutide has received FDA Fast Track Designation for MASH, which may accelerate its regulatory pathway for that specific indication. Retatrutide's Phase 3 program covers obesity and type 2 diabetes.
Both target liver disease through glucagon receptor agonism. Survodutide has more published liver-specific data: Phase 2 showed 62% of patients at 4.8 mg achieved histological MASH improvement versus 14% on placebo, and it holds FDA Fast Track Designation for MASH. Retatrutide Phase 3 MASH data is pending but its triple mechanism may deliver comparable or greater liver benefits.
Neither compound is available by prescription or through legitimate channels outside clinical trials. Research chemical suppliers may offer non-GMP synthesized versions of retatrutide, but quality and safety cannot be verified. Survodutide has no reported research chemical availability.